Premium
Philadelphia‐chromosome‐negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia
Author(s) -
Carella Angelo M.,
Frassoni Francesco,
Pollicardo Nicoletta,
Pungolino Ester,
Ferrero Raffaella,
Vasallo Franca,
Soracco Monica,
Giordano Domenico,
Figari Osvaldo,
Benvenuto Federica,
Florio Gaetano,
Carlier Paolo,
Valbonesi Mauro
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb08360.x
Subject(s) - leukapheresis , medicine , idarubicin , etoposide , chemotherapy , cyclophosphamide , stem cell , aplasia , transplantation , immunology , oncology , cytarabine , biology , cd34 , genetics
Ten patients in first or second relapse with Philadelphia chromosome acute lymphoblastic leukaemia, ineligible for allogeneic sibling marrow transplantation, were treated with an intensive chemotherapy regimen including idarubicin, intermediate‐dose arabinosylcytosine, etoposide and G‐CSF. Peripheral blood stem cells were collected by leukapheresis during initial early WBC recovery from chemotherapy‐Induced aplasia. In 5/10 patients all metaphases in leukapheresis products were found to be Philadelphia‐chromosome‐negative and they have been used as autotransplants after conditioning with TBI/etoposide/cyclophosphamide (or idarubicin) and G‐CSF. All five patients showed sustained engraftment and one of them is alive and well Philadelphia‐chromosome‐negative 18 months after transplant. These preliminary results suggest that it is possible to recover Philadelphia‐chromosome‐negative blood stem cells after intensive chemotherapy, even in advanced patients, and to perform autografting with these cells.